Kornimate/medical-research-clean huggingface dataset:
letrozole pretreatment with misoprostol finduction of abortion in first-trimester missed miscarriage

Conditions: Miscarriage; Missed Abortion

Summary: this study compares the success rate of letrozole and misoprostol versus misoprostol alone for medical termination of first trimester pregnancy.

according to the american college of obstetricians and gynecologists (2005), medical abortion is an acceptable alternative for surgical procedures in pregnant women with gestational age of less than 49 days based on the last menstrual period oral or vaginal misoprostol causes complete abortion in almost 85% of cases within seven days before the 12th week letrozole administration with misoprostol raises the rate of complete abortion hypothesis: in women with missed miscarriage in the first trimester undergoing induction of abortion pre-treatment with letrozole before misoprostol may lead to abortion rate similar to misoprostol alone.

Eligibility criteria:
inclusion criteria: * gestational age less than 64 days gestation (\<9 wks). * hemoglobin \>10 g/dl. * bmi between 18.5 kg/m2 and 25 kg/m2. * missed abortion. exclusion criteria: * molar pregnancy. * fibroid uterus. * uterine anomalies. * coagulopathy. * medical disorder that contraindicate induction of abortion (e.g. heart failure). * previous attempts for induction of abortion in the current pregnancy. * allergy to misoprostol or letrozole.
immune response to hepatitis b vaccine challenge dose in subjects who received a primary neonatal hepatitis b vaccine.

Conditions: Hepatitis B

Summary: the current study will evaluate immunological memory to hepatitis b antigen in subjects who received primary neonatal vaccination of hepatitis b vaccine (engerix™-b ), 20 years ago in the primary study and who have anti-hbs antibody concentrations \< pre-defined cut-off values at the previous long-term time point. all participating subjects will receive a challenge dose of hepatitis b vaccine. subjects will be aged approximately 20-21 years at the time of this study. no new subjects will be recruited in this long-term follow-up study. blood sampling will be done one month after the administration of the challenge dose. the protocol posting has been updated in order to comply with the fda amendment act, sep 2007.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * a male or female adult who received the complete neonatal primary vaccination course of hepatitis b vaccine in primary study approximately 20 years earlier. * documented level of anti-hbs antibody concentrations \< specified concentration at the previous long-term time point for which serological results are available for that subject. * written informed consent obtained from the subject. * healthy subjects as established by medical history and clinical examination before entering into the study. * if the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the hepatitis b challenge dose. exclusion criteria: * chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the hepatitis b vaccine challenge dose. * administration of a vaccine not foreseen by the study protocol during the study period. * administration of immunoglobulins and/or any blood products during the study period. * drug and/or alcohol abuse.

Keywords: hepatitis b vaccine challenge dose
study of the impact of an intervention performed by a clinical pharmacist on patients at risk of pneumococcal infection at the end of hospitalization

Conditions: Vaccination

Summary: in france, streptococcus pneumoniae is the leading agent involved in community-acquired bacterial pneumopathies and bacterial meningitis. the frequency of these infections is increasing in at-risk subjects. paradoxically, pneumococcal vaccination coverage in this type of patient is limited at the national level, even though the french high council for public health (hcsp) has been extending the 13-valent conjugate and 23-valent non-conjugate double vaccination in this target population since march 2017. these patients generally benefit from regular medical follow-up involving several health professionals in hospital or outpatient clinics. in spite of this, one of the factors identified as a hindrance to pneumococcal vaccination is the absence of a proposal from the doctor. we would like to assess compliance with the recommendations for pneumococcal vaccination according to the high council of public health (hcsp) in at-risk patients leaving hospital. we also wish to measure the potential impact of an intervention by the clinical pharmacist on the application of these recommendations.


Eligibility criteria:
inclusion criteria: * hospitalization in one of the departments participating in the study * at risk of pneumococcal infection according to hcsp recommendations (1) * negative pneumococcal vaccination status * adult patient (≥18 years old) exclusion criteria: * under safeguard of justice * unable to receive informed information * patient having objected to the use of their data.

Keywords: antipneumococcal
different clinicopathological features of non-elderly sigmoid volvulus patients

Conditions: Pathology

Summary: sigmoid volvulus is frequently seen in male patients over 60 years old. in the sigmoid volvulus \<60 age groups, the male/female ratio is close to each other. if sigmoid volvulus develops in \<60 age groups, it is more likely to be another underlying organic pathology.

sigmoid volvulus is frequently seen in male patients over 60 years old. here, the investigators aimed to investigate the causes of sigmoid volvulus developing in patients under 60 years of age. patients diagnosed with sigmoid volvulus between 2009 and 2018 were retrospectively screened. the patients were divided into two as under 60 years old and above. the co-morbidity, mortality, morbidity, complications, age and gender data of the patients were analyzed. in the sigmoid volvulus \<60 age groups, the male/female ratio is close to each other. if sigmoid volvulus develops in \<60 age groups, it is more likely to be another underlying organic pathology.

Eligibility criteria:
inclusion criteria: * sigmoid volvulus patients under the age of 60 * sigmoid volvulus patients at the age of ≥60 exclusion criteria: * lack of data

Keywords: dolichocolon volvulus sigmoid parkinson mental retardation hirschsprung's disease
study to evaluate the response to supplementation with postbiotics in patients with macular degeneration.

Conditions: AMD; Soft Drusen; Reticular Pseudodrusen; Drusen Stage Macular Degeneration; Drusen (Degenerative) of Macula, Bilateral

Summary: a pilot study to establish the efficacy and safety of supplementation with postbiotics in patients with macular degeneration.


Eligibility criteria:
inclusion criteria: * subjects of either gender aged 50 years or older with high risk intermediate amd defined as the following criteria: \>4 areas of at least irora or iora (incomplete rpe and outer retinal atrophy and incomplete outer retinal atrophy). 1 area of crora + 2 \> areas of irora. \< 1 mm2 of crora (complete rpe and outer retinal atrophy). no exudative neovascular amd. exclusion criteria: best corrected visual acuity in the study eye less than 20/400 by etdrs. not ability to provide written informed consent. not ability to return for all trial visits. if subject cannot attend all trial required visits. ga secondary to any condition other than specified. any ocular condition in the study eye that would progress during the study that could affect central vision or otherwise be a confounding factor. concomitant treatment with any ocular or systemic medication that is known to be toxic to the lens, retina or optic nerve. anti -vegf therapy is allowed in cohort b. presence of intraocular inflammation (≥ trace cell or flare), macular hole, pathologic myopia, epiretinal membrane, evidence of significant vitreo-retinal traction maculopathy, vitreous hemorrhage or aphakia (pseudophakia with or without an intact capsule is not an exclusion criteria). presence of idiopathic or autoimmune-associated uveitis in either eye. significant media opacities, including cataract, which might interfere with visual acuity, assessment of toxicity, fundus photography or fundus autofluorescence. subjects should not be entered if there is likelihood that they will require cataract surgery in the study eye in the following year. any intraocular surgery or thermal laser within three (3) months of trial entry. any prior thermal laser in the macular region, regardless of indication. history of any of the following procedures: posterior vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant or retinal detachment. previous therapeutic radiation in the region of the study eye. any treatment with an investigational agent in the past 60 days for any condition. pregnant or nursing women. additionally, women with childbearing potential must be using at least two effective contraception methods.

Keywords: postbiotic vitamins drusen intermediate amd
tele-rehabilitation to improve mild traumatic brain injury recovery and reduce subsequent injury risk

Conditions: Brain Concussion

Summary: the goal of this clinical trial is to examine the feasibility, utility, and efficacy of a smartphone-based assessment battery and remotely administered virtual neuromuscular/dual-task (vndt) intervention among healthy u.s. military service members and physically active young adults with a recent concussion.

aim 1. determine the baseline neuromuscular/dual-task performance characteristics among a sample of active-duty military service members compared to physically active young adult civilians. the investigators hypothesize that active-duty military service members will have similar baseline gait and dual-task abilities as civilians, demonstrating translation potential between populations. the investigators also hypothesize that baseline gait and dual-task abilities will be influenced by history of prior mtbi injuries among military service members. aim 2. examine the efficacy of a smartphone-based vndtt intervention to reduce musculoskeletal injury and improve neuromuscular/dual-task performance after a recent mtbi. the investigators hypothesize that those randomized to the intervention within three weeks of mtbi will have a lower risk of msk injury in the 3-month period following mtbi, relative to standard-of-care. the investigators also hypothesize that those randomized to the intervention within three weeks of mtbi will have better post-intervention gait and dual-task performance than those assigned to standard-of-care, despite similar baseline performance.

Eligibility criteria:
inclusion criteria: * 18-40 years of age at the time of enrollment * mild tbi or concussion diagnosis by a physician * confirmed mtbi diagnosis via va/dod guidelines at time of enrollment * participation in regular physical activity prior to injury (confirmed via the global physical activity questionnaire \[gpaq\]) (cleland et al., 2014; keating et al., 2019) * access to a smartphone for app download exclusion criteria: * moderate or severe tbi * pre-injury neurological disorder * abnormal brain imaging findings (if performed as a part of routine care) * previous tbi (mild/moderate/severe) \<12 months prior to enrollment other than the current injury for which they are being seen
intraperitoneal ropivacaine nebulization for pain control after laparoscopic surgery

Conditions: Laparoscopic Cholecystectomy

Summary: the purpose of this study is to assess if intraperitoneal nebulization of ropivacaine 50 mg, 100 mg or 150 mg may prevent the use of morphine during the first day after laparoscopic cholecystectomy.

intraperitoneal aerosolization of bupivacaine 50 mg after laparoscopic cholecystectomy has been proved to significantly reduce postoperative pain, morphine consumption and incidence of postoperative nausea and vomiting in comparison with patients receiving direct instillation of bupivacaine 50 mg or placebo. ropivacaine can be effectively administrated with non-heating nebulizers (aeronebpro®). in a recent study our group found that nebulization of ropivacaine 30 mg with the aeronebpro® before or after laparoscopic cholecystectomy significantly reduced postoperative pain and morphine consumption. nonetheless, most patients still need strong opioid based analgesia after surgery. we hypothesize that intraperitoneal nebulization of ropivacaine 100 mg and 150 mg (maximum recommended dose in adults 300 mg or up to 3 mg/kg) may prevent the use of morphine during the first day after surgery maintaining ropivacaine plasma levels below toxic concentration.

Eligibility criteria:
inclusion criteria: * females and males 18-75 years old * asa score i-iii * scheduled for laparoscopic cholecystectomy * free from pain in preoperative period * not using analgesic drugs before surgery * without cognitive impairment or mental retardation * written informed consent exclusion criteria: * emergency/urgency surgery * postoperative admission in an intensive care unit * cognitive impairment or mental retardation * progressive degenerative diseases of the cns * seizures or chronic therapy with antiepileptic drugs * severe hepatic or renal impairment * pregnancy or lactation * allergy to one of the specific drugs under study * acute infection or inflammatory chronic disease * alcohol or drug addiction

Keywords: laparoscopic cholecystectomy nebulization ropivacaine
comparing the effects of water temperature and actives in glucose solution on pregnant women

Conditions: Gestational Diabetes Mellitus

Summary: to assess the effect of water temperature and additives on pregnant women's taste and side effect during the oral glucose tolerance test (ogtt) evaluation.


Eligibility criteria:
inclusion criteria: * pregnant women * gestational age between 24 and 28 weeks exclusion criteria: * clinical diagnosis of overt type 2 diabetes * clinical diagnosis of facial palsy * clinical diagnosis of oral cavity and throat * clinical diagnosis of hypothyroidism * clinical diagnosis of chronic hepatitis * clinical diagnosis of kidney disease .clinical diagnosis of sicca syndrome.
efficacy of transversus thoracis muscle plane block in patients undergoing cardiac surgery

Conditions: Postoperative Pain

Summary: the goal of this randomized double blind study is to evaluate the analgesic efficacy of transversus thoracis muscle plane block in patients undergoing cardiac surgery with median sternotomy. one group of participants will receive multimodal analgesia plus ultrasound-guided transversus thoracis muscle plane block with ropivacaine 0.5 % after induction of general anesthesia, the other group will receive multimodal analgesia without a bloc. the investigators want to know if participants who receive the transversus thoracis muscle plane block with ropivacaine have less pain than participants who do not receive a block.

participants who undergo elective cardiac surgery with median sternotomy are eligible. they will receive general anaesthesia with multimodal analgesia as is standard in our institution. for study purposes participants will be randomized in a double blinded fashion to receive a transversus thoracis muscle plane block with 30 ml of ropivacaine 0.5 %, or no block. as the block is carried out after induction of general anesthesia the participants will not know to which group they are assigned. all blocks will be carried out after induction of general anesthesia, under full sterile precautions, and with ultrasound guidance. multimodal analgesia intra- and postoperatively is standardized and consists of: sufentanil, ketamine, dexmedetomidine, dexamethasone, paracetamol, metamizole, iv morphine in icu. the investigators aim for fast track surgery, i.e. extubation either in the operating room or in icu within the first 6 postoperative hours. the primary outcome is postoperative opioid consumption over the first 24 h postoperatively, secondary outcomes are pain scores and opioid-related side effects. all outcomes will be assessed by blinded investigators.

Eligibility criteria:
inclusion criteria: * • informed consent * major adult (≥ 18 years old) * body weight ≥ 50 kg. 50 kg is the minimal weight to ensure that participants will not receive an overdose of local anesthetic (ropivacaine 3 mg/kg) * primary cardiac surgery via a sternotomy approach * planned for fast-track procedure (i.e. postoperative extubation time of maximum six hours) exclusion criteria: * • participation in another study within the 30 days preceding and during the present study * refusal and/or inability to understand or sign the informed consent * emergency cardiac surgery * previous cardiac surgery * hypersensitivity or allergy to ropivacaine and other amide-class la * history of chronic pain * history of substance abuse * severe cardiac dysfunction (i.e. lvef ≤ 35%) * severe obesity (bmi \> 40kg/m2)
ultrasound utility in routine clinical practise

Conditions: Arthritis, Rheumatoid; Ultrasonography

Summary: the aim of this research study is to describe the impact of rheumatologist performed ultrasound on the diagnosis and management pathways of patients with rheumatoid arthritis. primarily, to compare the time from first visit to treatment initiation between patients with and without rheumatologist-performed ultrasound assessment.

there are currently no guidelines for best practice in the use of ultrasound in ra and interim results from a survey by the british society of rheumatology (bsr) in this area have suggested that practice is variable across the uk. nice recognize that the earlier persistent synovitis is identified and treated with disease modifying anti-rheumatic drugs dmards, the better the long term outcome and have welcomed the need to determine the role of imaging in assisting with this early diagnosis, and whether the added cost is justified by better disease outcomes. this is a multi-site prospective observational study which investigates the use of ultrasound imaging in the context of patients with early arthritis presenting to secondary care. the time to commencement of dmard therapy and diagnosis of rheumatoid arthritis are therein outcome measures. patients are followed up for 12 months after their first presentation and time to diagnosis or dmard commencement recorded.

Eligibility criteria:
inclusion criteria: * patients aged ≥18 years at the time of presentation to the clinic patients newly presenting to the rheumatology clinic with suspected inflammatory arthritis exclusion criteria: * for the non-ultrasound arm; patients who have been referred to another rheumatologist or radiologist for ultrasound patients who decline or who are unable to consent to the use of their medical records for research
assessment of ons-flavour preference in cancer patients with and without taste alterations

Conditions: Oncology; Taste, Altered

Summary: a single arm intervention study examining ons-flavour preference in cancer patients with and without taste alterations


Eligibility criteria:
inclusion criteria: 1. being diagnosed with cancer 2. undergoing, or having undergone systemic anti-cancer treatment or radiotherapy in the past 12 months. 3. age \> 18 years 4. written informed consent exclusion criteria: 1. taste and smell alterations not caused by the cancer or anti-cancer treatment 2. galactosaemia 3. use of thickener to be able to swallow safely 4. allergies to any of the product ingredients or any of the flavours 5. current prescription for ons, enteral nutrition or parenteral nutrition 6. diabetes mellitus type i or type ii 7. open sores or severe inflammation in the mouth or throat 8. undergoing dialysis 9. hepatic encephalopathy 10. patients with heart failure who have symptoms of heart failure at rest and/or are unable to carry on any physical activity without discomfort 11. known pregnancy or lactation 12. average alcohol use of \> 21 glasses per week for men or \> 14 glasses per week for women or drug abuse in opinion of the investigator 13. investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements 14. participation in any other studies involving food products concomitantly or within two weeks prior to entry into the study. 15. employees of nutricia research and/or partners, parents, children and brothers/sisters of employees

Keywords: oral nutritional supplement oncology taste alterations
using multimedia technology for hypertension control for low-income african americans

Conditions: Hypertension

Summary: the purpose of this study is to test an interactive dvd intervention to encourage patients to stick to their blood pressure medication in order to achieve blood pressure control for african american patients. the intervention will convey health messages through personal patient stories who have dealt with or continue to struggle with high blood pressure. hypothesis 1: at the end of 9 months a higher proportion of patients randomized to the intervention group will achieve appropriate blood pressure control. hypothesis 2: at the end of 9 months a higher proportion of patients who randomized to the intervention group will report high adherence to their hypertension medications.


Eligibility criteria:
inclusion criteria: * african american * clinical diagnosis of hypertension * patient at cooper green hospital * provided informed consent * age 18 or older exclusion criteria: * pregnant * diagnosed with dementia, schizophrenia, bipolar illness, or other serious acute or chronic medical co-morbidity

Keywords: hypertension adherence to medications
investigation of the pharmacokinetics of turoctocog alfa in subjects with haemophilia a

Conditions: Congenital Bleeding Disorder; Haemophilia A

Summary: this trial is conducted in europe. the aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body) of four lots of turoctocog alfa (a human recombinant coagulation factor viii (fviii)) in subjects with haemophilia a.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities. trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * male subjects with the diagnosis of severe haemophilia a (fviii\<1%) from age 18 years * documented history of at least 150 exposure days to any other fviii products (prevention or treatment of bleeds) * immunocompetent (hiv (human immunodeficiency virus) positive subjects should have cd4+ (cluster of differentiation 4; a glycoprotein expressed on the surface) lymphocyte count \>200/microl) exclusion criteria: * detectable inhibitors to fviii (above or equal to 0.6 bethesda units (bu)) * history of fviii inhibitors * severe current hepatic dysfunction or severe hepatic disease during the last 12 months * known or suspected allergy to trial product (fviii) or related products * subjects receiving immune modulating medication or immune tolerance induction (iti) regimens * body mass index (bmi) above 30 kg/m\^2